PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Med Genet. 1993 June; 30(6): 492–496.
PMCID: PMC1016423

Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Abstract

Most forms of osteogenesis imperfecta are caused by dominant mutations in either of the two genes, COL1A1 and COL1A2, that encode the pro alpha 1(I) and pro alpha 2(I) chains of type I collagen, respectively. However, a severe, autosomal recessive form of OI type III with a comparatively high frequency has been recognised in the black populations of southern Africa. We preformed linkage analyses in eight OI type III families using RFLPs associated with the COL1A1 and COL1A2 loci to determine whether mutations in the genes for type I collagen were responsible for this form of OI. Recombination between the OI phenotype and polymorphic markers at both loci was shown in three of the eight families investigated. The combined lod scores for the eight families were -10.6 for COL1A1 and -11.2 for COL1A2. Further, we examined the type I procollagen produced by skin fibroblast cultures derived from 15 affected and 12 unaffected subjects from the above eight families plus one further family. We found no evidence for defects in the synthesis, structure, secretion, or post-translational modification of the chains of type I procollagen produced by any of the family members. These results suggest that mutations within or near the type I collagen structural genes are not responsible for this form of OI.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (879K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr;16(2):101–116. [PMC free article] [PubMed]
  • Sillence DO, Barlow KK, Cole WG, Dietrich S, Garber AP, Rimoin DL. Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet. 1986 Mar;23(3):821–832. [PubMed]
  • Wenstrup RJ, Willing MC, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am J Hum Genet. 1990 May;46(5):975–982. [PubMed]
  • Starman BJ, Eyre D, Charbonneau H, Harrylock M, Weis MA, Weiss L, Graham JM, Jr, Byers PH. Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype. J Clin Invest. 1989 Oct;84(4):1206–1214. [PMC free article] [PubMed]
  • Pruchno CJ, Cohn DH, Wallis GA, Willing MC, Starman BJ, Zhang XM, Byers PH. Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen. Hum Genet. 1991 May;87(1):33–40. [PubMed]
  • Wenstrup RJ, Shrago-Howe AW, Lever LW, Phillips CL, Byers PH, Cohn DH. The effects of different cysteine for glycine substitutions within alpha 2(I) chains. Evidence of distinct structural domains within the type I collagen triple helix. J Biol Chem. 1991 Feb 5;266(4):2590–2594. [PubMed]
  • Pack M, Constantinou CD, Kalia K, Nielsen KB, Prockop DJ. Substitution of serine for alpha 1(I)-glycine 844 in a severe variant of osteogenesis imperfecta minimally destabilizes the triple helix of type I procollagen. The effects of glycine substitutions on thermal stability are either position of amino acid specific. J Biol Chem. 1989 Nov 25;264(33):19694–19699. [PubMed]
  • Deak SB, Nicholls A, Pope FM, Prockop DJ. The molecular defect in a nonlethal variant of osteogenesis imperfecta. Synthesis of pro-alpha 2(I) chains which are not incorporated into trimers of type I procollagen. J Biol Chem. 1983 Dec 25;258(24):15192–15197. [PubMed]
  • Nicholls AC, Osse G, Schloon HG, Lenard HG, Deak S, Myers JC, Prockop DJ, Weigel WR, Fryer P, Pope FM. The clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta. J Med Genet. 1984 Aug;21(4):257–262. [PMC free article] [PubMed]
  • Aitchison K, Ogilvie D, Honeyman M, Thompson E, Sykes B. Homozygous osteogenesis imperfecta unlinked to collagen I genes. Hum Genet. 1988 Mar;78(3):233–236. [PubMed]
  • Beighton P, Versfeld GA. On the paradoxically high relative prevalence of osteogenesis imperfecta type III in the black population of South Africa. Clin Genet. 1985 Apr;27(4):398–401. [PubMed]
  • Viljoen D, Beighton P. Osteogenesis imperfecta type III: an ancient mutation in Africa? Am J Med Genet. 1987 Aug;27(4):907–912. [PubMed]
  • Horan F, Beighton P. Autosomal recessive inheritance of osteogenesis imperfecta. Clin Genet. 1975 Aug;8(2):107–111. [PubMed]
  • Tsipouras P, Myers JC, Ramirez F, Prockop DJ. Restriction fragment length polymorphism associated with the pro alpha 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. J Clin Invest. 1983 Oct;72(4):1262–1267. [PMC free article] [PubMed]
  • Grobler-Rabie AF, Brebner DK, Vandenplas S, Wallis G, Dalgleish R, Kaufman RE, Bester AJ, Mathew CG, Boyd CD. Polymorphism of DNA sequence in the human pro alpha 2(I) collagen gene. J Med Genet. 1985 Jun;22(3):182–186. [PMC free article] [PubMed]
  • Sykes B, Ogilvie D, Wordsworth P, Anderson, Jones N. Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet. 1986 Jul 12;2(8498):69–72. [PubMed]
  • Vandenplas S, Wiid I, Grobler-Rabie A, Brebner K, Ricketts M, Wållis G, Bester A, Boyd C, Måthew C. Blot hybridisation analysis of genomic DNA. J Med Genet. 1984 Jun;21(3):164–172. [PMC free article] [PubMed]
  • Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. [PubMed]
  • Dalgleish R, Trapnell BC, Crystal RG, Tolstoshev P. Copy number of a human type I alpha 2 collagen gene. J Biol Chem. 1982 Nov 25;257(22):13816–13822. [PubMed]
  • Tajima S, Ting JP, Pinnell SR, Kaufman RE. Isolation and characterization of a human pro alpha 2(I) collagen gene segment. J Invest Dermatol. 1984 Mar;82(3):265–269. [PubMed]
  • Grobler-Rabie AF, Wallis G, Brebner DK, Beighton P, Bester AJ, Mathew CG. Detection of a high frequency RsaI polymorphism in the human pro alpha 2(I) collagen gene which is linked to an autosomal dominant form of osteogenesis imperfecta. EMBO J. 1985 Jul;4(7):1745–1748. [PubMed]
  • Baker R, Lynch J, Ferguson L, Priestley L, Sykes B. PCR detection of five restriction site dimorphisms at the type I collagen loci COL1A1 and COL1A2. Nucleic Acids Res. 1991 Aug 11;19(15):4315–4315. [PMC free article] [PubMed]
  • Lathrop GM, Lalouel JM. Easy calculations of lod scores and genetic risks on small computers. Am J Hum Genet. 1984 Mar;36(2):460–465. [PubMed]
  • Bonadio J, Holbrook KA, Gelinas RE, Jacob J, Byers PH. Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta. J Biol Chem. 1985 Feb 10;260(3):1734–1742. [PubMed]
  • Barsh GS, Byers PH. Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5142–5146. [PubMed]
  • Cohn DH, Byers PH. Clinical screening for collagen defects in connective tissue diseases. Clin Perinatol. 1990 Dec;17(4):793–809. [PubMed]
  • Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC. Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. Am J Hum Genet. 1988 Feb;42(2):237–248. [PubMed]
  • Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beighton P, Nicholls A, Pope FM, Thompson E, Tsipouras P, et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet. 1990 Feb;46(2):293–307. [PubMed]
  • Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet. 1991 Jul;28(7):433–442. [PMC free article] [PubMed]
  • Cohn DH, Starman BJ, Blumberg B, Byers PH. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1). Am J Hum Genet. 1990 Mar;46(3):591–601. [PubMed]
  • Wallis GA, Starman BJ, Zinn AB, Byers PH. Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent. Am J Hum Genet. 1990 Jun;46(6):1034–1040. [PubMed]
  • Cohen-Solal L, Bonaventure J, Maroteaux P. Dominant mutations in familial lethal and severe osteogenesis imperfecta. Hum Genet. 1991 Jul;87(3):297–301. [PubMed]
  • Bateman JF, Chan D, Walker ID, Rogers JG, Cole WG. Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen. J Biol Chem. 1987 May 25;262(15):7021–7027. [PubMed]
  • Sandberg MM. Matrix in cartilage and bone development: current views on the function and regulation of major organic components. Ann Med. 1991 Aug;23(3):207–217. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group